Advertisement
News|Videos|October 15, 2026
Jonathan Myers, M.D., on home VR perimetry and glaucoma reimbursement
A two-year study of 53 glaucoma patients logged nearly 4,800 home VR visual field tests, yet no insurance code currently covers home perimetry.
Virtual reality goggles could let patients with glaucoma track their visual fields from home, but the lack of insurance reimbursement remains one of the major barriers to adoption M.D.,
chief of Glaucoma Service at Wills Eye Hospital in Philadelphia
Myers and his colleagues presented the data at the 2026 American Academy of Ophthalmology
in a poster session titled ‘High-Frequency Home Monitoring of Glaucoma With Virtual Reality Perimetry: A 2-Year Prospective Longitudinal Study.’
Myers and colleagues conducted a two-year study of home virtual reality perimetry in 53 patients with glaucoma, using a headset platform from Olleyes, one of roughly two dozen commercially available virtual reality perimetry systems. Participants completed nearly 4,800 home tests over the study period, alongside more than 750 traditional visual field tests in the office. The team is continuing to analyze the data. At 24 months, adherence was 87% by the study’s measure, with most participants still testing at least monthly.
Earlier work from Myers’ group and other investigators found that virtual reality goggles produced results similar to conventional desktop perimetry when used in the office. The open questions, he said, are whether the test performs as well at home without an ophthalmic technician coaching patients to stay engaged, whether patients will keep testing as directed over time, and whether more frequent testing can detect worsening sooner. Because visual field results fluctuate from test to test, a larger volume of tests may help clinicians spot progression earlier. “Maybe if we do more tests, we’ll be able to tell earlier if people are getting worse from glaucoma,” Myers said.
There is currently no insurance code for home perimetry, Myers noted, which means no reimbursement pathway for the hardware, the software, the physician’s interpretation or patient counseling. He compared the situation to home blood glucose and blood pressure monitoring, which now have durable medical equipment and physician billing codes that support patient access. “We need that in glaucoma for home perimetry,” he said.
Myers acknowledged that most physicians are cautious about adopting new technology until it is proven safe and effective and said the science is not yet fully there for many of these devices. Insurers may make a similar argument against funding home testing, a concern the two-year study was designed in part to address. “So hopefully we now have a data set that can really speak to the concerns of the insurers in terms of the value,” he said.
Related to this article
October 15th, 2026
Pope Leo XIV’s lung cancer diagnosis puts a spotlight on low U.S. screening rates
The pope’s lung nodule was found during a routine exam. In the U.S., only 18.7% of adults eligible for lung cancer screening are up to date.
Read more
October 15th, 2026
A conversation about access and affordability with Will Carroll, chief pharmacy officer at Sutter Health
Ahead of the Health System Executive Summit, Will Carroll, chief pharmacy officer at Sutter Health, shares the system’s pharmacy strategy, its approach to building a leadership pipeline and advice for pharmacy leaders seeking a stronger executive voice.
Read more
October 15th, 2026
A conversation about navigating the day-to-day of being a chief medical officer, with Rex Hoffman, M.D., MBA, CMO of Providence Holy Cross Medical Center
Rex Hoffman, M.D., MBA, chief medical officer of Providence Holy Cross Medical Center, discusses his transition from radiation oncologist to hospital executive and the panel discussion that led to his new book, “Difficult Dilemmas for Chief Medical Officers: 30 Case Studies.”
Read more
October 14th, 2026
Economics must align to scale CAR-T therapy access, per Dan Nardi of Reimagine Care
Reimagine Care’s CEO says one-off hospital approvals slow CAR-T access and urges buyers to ask vendors to prove outcomes such as avoided ED visits.
Read more
October 14th, 2026
Why biosimilars keep losing ground to brand-name rivals: A Q&A with Christine Johnston, MBA
Foundational Pharmacy Strategies’ Christine Johnston on how rebate structures, pending legislation, and a stalled pipeline are reshaping — and threatening — the biosimilar market heading into 2027.
Read more
October 13th, 2026
Katie Martin, M.P.A., has 3 messages for employers paying healthcare costs
The financial pain from your healthcare cost is real, you are uniquely placed to negotiate prices down, and hospitals, at 46% of spending, are where to look, says the CEO and president of the Health Care Cost Institute, which issued its annual cost and utilization report today.
Read more
October 13th, 2026
Katie Martin, M.P.A., on soaring prescription drug spending and relatively stable out-of-pocket costs
Spending on prescription drugs grew by 40%, faster than spending on inpatient care, outpatient care and professional services, according to a new report from the Health Care Cost Institute.
Read more
October 13th, 2026
Pregnancies conceived through assisted reproduction linked to higher risk of major heart defects
Meta-analysis links assisted reproduction tech (ART) to higher risks of major heart defects in pregnancies, urging targeted screening and long-term heart health follow-up.
Read more
Advertisement
Advertisement
